New drug combo aims to shrink tumors and spare rectums

NCT ID NCT06864013

Recruiting now Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

Summary

This study is testing a new treatment approach for people with a common type of advanced rectal cancer. It combines a short course of radiation, standard chemotherapy, and two new immunotherapy drugs to try to shrink tumors before surgery. The main goal is to see if this combination helps more patients achieve a complete response, potentially allowing them to avoid major surgery and preserve organ function.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310006, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED RECTAL CANCER (LARC)